| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
ACTH (18-39) targets melanocortin receptors and other receptors involved in adrenal cortex function regulation. As a corticotropin-like intermediate lobe peptide, it interacts with melanocortin receptors in the adrenal cortex. Its precise receptor binding profile and functional activity are subjects of ongoing research.
|
|---|---|
| ln Vitro |
In vitro, ACTH (18-39) is used in research settings to explore its role in the regulation of adrenal cortex function and its interaction with specific receptors. It binds to melanocortin receptors and may modulate steroidogenesis. Its activity is characteristic of corticotropin-like peptides.
|
| ln Vivo |
In vivo activity data for ACTH (18-39) are limited. As a peptide fragment of ACTH, it may have biological activity related to adrenal cortex function. It is produced endogenously in the pituitary gland. Further in vivo studies are needed to fully characterize its physiological role.
|
| Enzyme Assay |
In vitro receptor binding assays for ACTH (18-39) are conducted using cells expressing melanocortin receptors (MC1R, MC2R, MC3R, MC4R, MC5R). Radioligand binding assays with [¹²⁵I]-ACTH or [¹²⁵I]-NDP-MSH are used to assess receptor binding affinity. Functional activity is measured by cAMP accumulation assays.
|
| Cell Assay |
Cellular assays for ACTH (18-39) are performed using adrenal cortex cell lines or primary adrenocortical cells. Cells are treated with peptide concentrations ranging from 0.1 nM to 10 µM for 1-24 hours. Steroid hormone production (e.g., cortisol, corticosterone) is measured by ELISA or radioimmunoassay. cAMP levels are measured to assess receptor activation.
|
| Animal Protocol |
In vivo animal studies for ACTH (18-39) are limited. Studies would typically involve administration of the peptide to rodents followed by assessment of adrenal function, including corticosteroid levels and adrenal gland weight. The peptide is not widely used in animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for ACTH (18-39) are limited. As a peptide, it is expected to have a short half-life due to rapid proteolytic degradation. It is not administered as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
ACTH (18-39) is a peptide and does not have established toxicity data. It is designated for research use only. Standard laboratory safety precautions apply.
|
| Additional Infomation |
ACTH (18-39), human TFA (CLIP human TFA) is a corticotropin-like intermediate lobe peptide produced in the melanotrophs of the pituitary gland. It is used in research to study adrenal cortex function and melanocortin receptor signaling. It is not a drug and has no clinical approval.
|
| Molecular Formula |
C114H166F3N27O38
|
|---|---|
| Molecular Weight |
2579.69117879868
|
| Exact Mass |
2579.187
|
| CAS # |
73724-75-1
|
| Related CAS # |
Adrenocorticotropic Hormone (ACTH) (18-39), human;53917-42-3
|
| PubChem CID |
155977634
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
33
|
| Hydrogen Bond Acceptor Count |
44
|
| Rotatable Bond Count |
76
|
| Heavy Atom Count |
182
|
| Complexity |
5730
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)N.C(=O)(C(F)(F)F)O
|
| InChi Key |
ZAPPDVOJVZTOMI-AEQSNVDMSA-N
|
| InChi Code |
InChI=1S/C112H165N27O36.C2HF3O2/c1-56(2)48-72(100(163)125-70(37-41-86(148)149)97(160)133-77(111(174)175)51-63-24-14-11-15-25-63)129-103(166)79-28-20-46-138(79)109(172)75(49-62-22-12-10-13-23-62)131-93(156)61(9)121-95(158)68(35-39-84(144)145)123-92(155)60(8)122-102(165)78(55-140)134-98(161)71(38-42-87(150)151)126-101(164)74(53-88(152)153)128-96(159)69(36-40-85(146)147)124-91(154)59(7)120-83(143)54-119-94(157)73(52-82(115)142)130-104(167)80-29-21-47-139(80)110(173)76(50-64-31-33-65(141)34-32-64)132-107(170)89(57(3)4)135-99(162)67(27-16-17-43-113)127-106(169)90(58(5)6)136-105(168)81-30-19-45-137(81)108(171)66(114)26-18-44-118-112(116)117;3-2(4,5)1(6)7/h10-15,22-25,31-34,56-61,66-81,89-90,140-141H,16-21,26-30,35-55,113-114H2,1-9H3,(H2,115,142)(H,119,157)(H,120,143)(H,121,158)(H,122,165)(H,123,155)(H,124,154)(H,125,163)(H,126,164)(H,127,169)(H,128,159)(H,129,166)(H,130,167)(H,131,156)(H,132,170)(H,133,160)(H,134,161)(H,135,162)(H,136,168)(H,144,145)(H,146,147)(H,148,149)(H,150,151)(H,152,153)(H,174,175)(H4,116,117,118);(H,6,7)/t59-,60-,61-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,89-,90-;/m0./s1
|
| Chemical Name |
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]acetyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;2,2,2-trifluoroacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~38.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (19.38 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3876 mL | 1.9382 mL | 3.8764 mL | |
| 5 mM | 0.0775 mL | 0.3876 mL | 0.7753 mL | |
| 10 mM | 0.0388 mL | 0.1938 mL | 0.3876 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
